OncoSec Medical (NSDQ:ONCS) announced today that it received CE mark approval for its next-generation device to enable better uptake of anti-cancer therapies.
GenPulse, part of OncoSec’s electroporation device platform for treating solid tumors, is designed to apply short electric impulses to a tumor, according to a news release.
The electric impulses cause pores to open in the membrane of cancer cells, significantly increasing the uptake of anti-cancer agents into those cells, OncoSec said.
OncoSec plans to commercially deploy the GenPulse gene electrotransfer device in both the U.S. and European Union, it also noted. The company has a focus on developing cytokine-based intratumoral immunotherapies to stimulate the body’s immune system to target and attack cancer.
“This CE certification is an essential regulatory milestone on OncoSec’s road to commercialization in Europe,” OncoSec SVP, regulatory quality & CMC Robert Ashworth said in the release. “The CE mark on our proprietary GenPulse generator represents the culmination of years of work and demonstrates that OncoSec has the capability to manufacture and develop a device that meets performance, quality and safety requirements in the EU.”